READ-POAF Pilot Studies Postoperative Atrial Fibrillation After Cardiac Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01530750|
Recruitment Status : Unknown
Verified August 2012 by Catharina Ziekenhuis Eindhoven.
Recruitment status was: Recruiting
First Posted : February 10, 2012
Last Update Posted : September 3, 2012
Postoperative atrial fibrillation after coronary artery bypass grafting will be monitored up to 1 year after the procedure by implanting a Reveal XT internal loop recorder two weeks before the surgery. Frequency, burden, and possible risk factors will be described.
During the operation direct contact epicardial mapping will be performed and tissue samples will be collected to identify an electrophysiological and a structural substrate for development of AF.
|Condition or disease|
Background of the study:
Postoperative atrial fibrillation (POAF) after cardiac surgery is a common (1 in 4) complication and associated with morbidity and mortality. Not all episodes of AF are noticed and detected, especially after discharge. several studies have shown high mortality in POAF patients, suggesting a progression in AF frequency.
Objective of the study:
To investigate the real incidence and burden of POAF. Afterwards a risk stratification of POAF is made. To identify a structural and electrophysiological substrate for the development of POAF and new onset AF during follow up.
140 patients will receive a Reveal device. After 3 and 12 months data will be subtracted from the device. 100 of these patient will undergo additional mapping and tissue biopsies during operation.
All patients undergoing cardiac surgery without a history of AF and without a pacemaker will be invited to participate in the study.
Primary study parameters/outcome of the study:
Incidence of POAF until 3 months after CABG.
Secondary study parameters/outcome of the study:
Incidence of POAF until 12 months after CABG. Determine risk factors for early and late POAF. Detect pre-operative (unnoticed) episodes of AF.
Determine a substrate for development of AF.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
There is a small risk of minor complications (hemorrhage and infection of the pocket).The device can be explanted easily if necessary. Ther is a burden of the im- and explantation of the device (local anesthesia, approx. 20 minutes). Patient will have to visit the out-hospital clinic twice.
The operation will be prolonged by 30 minutes due to mapping.
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||READ-POAF Pilot Study. The Use of the Reveal XT as Device for Postoperative Atrial Fibrillation Detection After Cardiac Surgery|
|Study Start Date :||March 2012|
|Estimated Primary Completion Date :||February 2013|
|Estimated Study Completion Date :||February 2014|
|Post cardiac surgery|
- atrial fibrillation (AF) [ Time Frame: 3 months ]frequency, frequency distribution, and burden of AF
- atrial fibrillation (AF) [ Time Frame: 12 months ]frequency, frequency distribution, burden of AF, AF substrate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01530750
|Contact: Sander Bramer, MDfirstname.lastname@example.org|
|Contact: Bramer email@example.com|
|Maastricht University Medical Center||Not yet recruiting|
|Contact: Bramer firstname.lastname@example.org|
|Principal Investigator:||Bart van Straten, MD, PhD||CZE|
|Study Director:||Sander Bramer, MD||CZE|
|Principal Investigator:||Jos Maessen, MD. PhD||Maastricht University Medical Center|